Modified immune cells seek and destroy melanoma

June 24, 2013

In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of the immune system, were tested in patients with melanoma. All cells express a complex known as the proteasome, which acts as the garbage disposal for the cell. There are two types of proteasomes: constitutive proteasomes (cPs), which are found in normal tissues, and immunoproteasomes (iPs), which are found in stressed or damaged cells. In a damaged cell, the iP generates protein fragments that are displayed on the surface of the distressed cells, triggering recognition by dendritic cells and subsequent destruction by the immune system.

Most cancers, including melanoma, exclusively express cPs, making it impossible for them to express the that are recognized by the immune system. To make it easier for the immune system to find cancer cells, Pruitt and colleagues engineered a specific type of immune cell, known as a dendritic cell, that recognizes protein fragments of cancer specific antigens made by cPs. The engineered dendritic cells were then injected into patients that were in remission from melanoma.

The trial consisted of 4 patients that were vaccinated with regular dendritic cells, 3 patients that received cells that underwent a control treatment, and 5 patients that received dendritic cells that recognized cancer-made protein fragments. Vaccination with all three types of dendritic cells elicited an immune response, which peaked after 3-4 vaccinations with dendritic cells. Patients that received the specially modified dendritic cells had a longer lasting immune response and fewer circulating . Of the two patients that had active disease, treatment with modified dendritic cells resulted in a partial clinical response in one and a complete clinical response in the other.

These results suggest that modification of so that they recognize cP-produced tumor antigens enhances immune recognition of melanoma cells.

Explore further: How the immune system positions its gatekeepers

Related Stories

How the immune system positions its gatekeepers

March 19, 2013
(Medical Xpress)—For an immune response to get underway, an invading microbe must first be halted in the spleen, and then digested by immune cells known as 'dendritic cells', which guard specific portals. Australian scientists ...

Cerebral malaria: Pinpointing a potential therapeutic target

January 16, 2013
An excessive response of the immune system to malarial infection can lead to serious complications, such as cerebral malaria. While the mechanism causing the onset of cerebral malaria is unclear, immunologists think that ...

Cancer 'turns off' important immune cells, complicating experimental vaccine therapies

August 30, 2012
A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new ...

Ebola's secret weapon revealed

May 2, 2013
Researchers have discovered the mechanism behind one of the Ebola virus' most dangerous attributes: its ability to disarm the adaptive immune system.

Discovery of immune cells that protect against multiple sclerosis offers hope for new treatment

August 16, 2012
In multiple sclerosis, the immune system attacks nerves in the brain and spinal cord, causing movement problems, muscle weakness and loss of vision. Immune cells called dendritic cells, which were previously thought to contribute ...

How excess alcohol depresses immune function

August 16, 2011
Alcoholism suppresses the immune system, resulting in a high risk of serious, and even life-threatening infections. A new study shows that this effect stems largely from alcohol’s toxicity to immune system cells called ...

Recommended for you

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.